Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
What you will learn in this article: Retatrutide is an investigational triple G agonisttargeting GLP-1, GIP, and glucagon receptorscurrently in Phase 3 clinical trials by Eli Lilly
What this means for the Indian market: Increased accessibility of Semaglutide therapy Greater competition leading to potential price rationalization Expansion of obesity management as a mainstream therapeutic segment A new strategic battleground for pharma marketing teams #PharmaIndustry #Semaglutide #DiabetesCare #ObesityManagement Mahesh Malhotra: One of our clients in the MENA region is exploring a Semaglutide technology transfer, preferably from a mid-sized pharma company
At 8mg, the Phase 2 trial showed 22.8% body weight reduction at 48 weeks
I've always been the funny fat guy
